Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Reviva Pharmaceuticals Holdings Inc (RVPHW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: RVPHW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.07% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.81M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.11 | 52 Weeks Range 0.02 - 0.52 | Updated Date 05/26/2025 |
52 Weeks Range 0.02 - 0.52 | Updated Date 05/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -178.72% | Return on Equity (TTM) -916.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 40777801 |
Shares Outstanding - | Shares Floating 40777801 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Reviva Pharmaceuticals Holdings Inc
Company Overview
History and Background
Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing therapies for central nervous system diseases. Founded in 2012, Reviva is working on treatments for schizophrenia, pulmonary hypertension and other disorders. Their lead drug candidate is Brilaroxazine.
Core Business Areas
- CNS Therapies: Development of therapies for central nervous system (CNS) diseases, including schizophrenia, bipolar disorder, and other neuropsychiatric conditions.
- Pulmonary Hypertension: Development of therapies to treat pulmonary hypertension
Leadership and Structure
The company is led by Dr. Laxminarayan Bhat, CEO, and has a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Brilaroxazine: Brilaroxazine is Reviva's lead drug candidate, a dopamine D2/serotonin 5-HT2A receptor modulator being developed for schizophrenia and pulmonary hypertension. Market share is currently 0% as the drug is still in clinical trials and not yet approved. Competitors: Johnson & Johnson (INVEGA SUSTENNA), Otsuka (ABILIFY MAINTENA), Alkermes (ARISTADA).
Market Dynamics
Industry Overview
The pharmaceutical industry for CNS disorders is large and growing, driven by increasing prevalence of mental health conditions. There's a significant unmet need for more effective and safer treatments.
Positioning
Reviva is a clinical-stage company aiming to differentiate itself through novel mechanisms of action and potential for improved efficacy and safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The global schizophrenia market is expected to reach billions of dollars. Reviva is positioned to capture a portion of this market if Brilaroxazine is approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Brilaroxazine)
- Potential for improved efficacy and safety
- Focus on unmet medical needs
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger competitors
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Regulatory approval and market launch of Brilaroxazine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and new therapies
- Patent expiration
Competitors and Market Share
Key Competitors
- JNJ
- OTSKF
- ALKS
Competitive Landscape
Reviva faces significant competition from established pharmaceutical companies with approved schizophrenia treatments. Reviva needs to demonstrate superior efficacy or safety to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is pre-revenue.
Future Projections: Future growth depends on successful clinical development and commercialization of Brilaroxazine. Analyst estimates depend on the successful completion of their trails.
Recent Initiatives: Recent initiatives include advancing clinical trials for Brilaroxazine in schizophrenia and pulmonary hypertension.
Summary
Reviva Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on developing treatments for CNS disorders. Its success hinges on the positive outcome of clinical trials for Brilaroxazine. The company faces significant competition and requires substantial funding to advance its pipeline. Positive clinical results would be a major catalyst, while trial failures could severely impact its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be delayed or inaccurate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Reviva Pharmaceuticals Holdings Inc
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2018-10-18 | Founder, CEO, President & Director Dr. Laxminarayan Bhat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.revivapharma.com |
Full time employees 14 | Website https://www.revivapharma.com | ||
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.